Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients
et al., Revista Espanola de Quimioterapia, doi:10.37201/req/130.2020
, Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients, Revista Espanola de Quimioterapia, doi:10.37201/req/130.2020
Retrospective 79 hospitalized nonagenarian patients showing unadjusted HCQ mortality RR 0.84, p = 0.76.Although the 16% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality [18‑27%] from meta analysis of the 232 mortality results to date.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
|
risk of death, 15.6% lower, RR 0.84, p = 0.76, treatment 33 of 67 (49.3%), control 7 of 12 (58.3%), NNT 11.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Roig et al., 31 Jan 2021, retrospective, Spain, peer-reviewed, 6 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.